International union of basic and clinical pharmacology. LXXXI. Nomenclature and classification of adenosine receptors - An update

Pharmacological Reviews

Volumn 63, Issue 1, 2011, Pages 1-34

  Fredholm, Bertil B ^a   IJzerman, Adriaan P ^b   Jacobson, Kenneth A ^c   Linden, Joel ^d   Müller, Christa E ^e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LEIDEN UNIVERSITY   (Netherlands)

^c NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^d LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^e UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2 METHYL 6 PHENYL 4 (2 PHENYLETHYNYL) 3,5 PYRIDINEDICARBOXYLIC ACID 5 BENZYL 3 ETHYL ESTER; 2 (2 FURYL) 5 [3 (4 METHOXYPHENYL)UREIDO] 8 PROPYLPYRAZOLO[4,3 E] 1,2,4 TRIAZOLO[1,5 C]PYRIMIDINE; 2 (2 HYDROXYETHYL) 1 [3 (2 PHENYLPYRAZOLO[1,5 A]PYRIDIN 3 YL)ACRYLOYL]PIPERIDINE; 2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 4 ANILINO 2 CYCLOPENTYLIMIDAZO[4,5 C]QUINOLINE; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 5 AMINO 2 (2 FURYL) 7 [3 (4 METHOXYPHENYL)PROPYL]PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 6 ETHYL 2 PHENYL 4 PROPYL 3 PYRIDINECARBOXYLIC ACID 5 THIOCARBOXYLIC ACID 5 ETHYL 3 PROPYL ESTER; 6 N (2 HYDROXYCYCLOPENTYL)ADENOSINE; 6 N (3 IODOBENZYL)ADENOSINE 5' N METHYLCARBOXAMIDE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5 PHENYLACETYLAMINO 1,2,4 TRIAZOLO[1,5 C]QUINAZOLINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; ADENOSINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; APADENOSON; ATL 313; ATL 802; BAY 60 6583; BIIB 014; BINODENOSON; BVT 115959; CAFFEINE; CAPADENOSON; CF 102; CF 503; CP 608 039; CT 3146; CVT 3619; CVT 6883; GS 6201; GS 9667; GW 493838; ISTRADEFYLLINE; KF 26777; LAS 38096; LUF 5981; LUF 6000; LUF 6096; LUV 6258; MRE 2029 F20; MRS 5151; MRS 592; MSX 2; N (4 CYANOPHENYL) 2 [4 (2,3,6,7 TETRAHYDRO 2,6 DIOXO 1,3 DIPROPYL 1H PURIN 8 YL)PHENOXY]ACETAMIDE; PD 120 918; PD 71 605; PD 81 723; PRELADENANT; PSB 10; PSB 11; PSB 1115; PSB 36; PSB 603; REGADENOSON; ROLOFYLLINE; SELODENOSON; SLV 320; SONEDENOSON; ST 1535; SYN 115; T 62; TECADENOSON; THEOPHYLLINE; TONAPOFYLLINE; UK 432097; UNCLASSIFIED DRUG; UNINDEXED DRUG; V 2006; VUF 5574;

ACUTE HEART INFARCTION; ALLOSTERISM; BINDING SITE; CLASSIFICATION; CLINICAL TRIAL; COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG EFFECT; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRY EYE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; INTRAOCULAR HYPERTENSION; LIGAND BINDING; NEUROPATHIC PAIN; NEWBORN APNEA; NONHUMAN; OLIGOMERIZATION; PARKINSON DISEASE; PERIPHERAL NERVE INJURY; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; PROTEIN STRUCTURE; RECEPTOR INTRINSIC ACTIVITY; REPERFUSION INJURY; REVIEW; RHEUMATOID ARTHRITIS; SINGLE NUCLEOTIDE POLYMORPHISM; STRUCTURE ACTIVITY RELATION; STRUCTURE ANALYSIS;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; HUMANS; INTERNATIONAL AGENCIES; MOLECULAR TARGETED THERAPY; PURINERGIC P1 RECEPTOR AGONISTS; PURINERGIC P1 RECEPTOR ANTAGONISTS; RECEPTORS, PURINERGIC P1; TERMINOLOGY AS TOPIC;

EID: 79952033865     PISSN: 00316997     EISSN: 15210081     Source Type: Journal    
DOI: 10.1124/pr.110.003285     Document Type: Review

References (276)

1. 2B adenosine receptor antagonists. J Pharmacol Exp Ther 308:358-366.
2. Al Jaroudi W and Iskandrian AE (2009) Regadenoson: a new myocardial stress agent. J Am Coll Cardiol 54:1123-1130.
3. Alsene K, Deckert J, Sand P, and de Wit H (2003) Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 28:1694-1702. (Pubitemid 41070870)
4. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Arlington, VA.
5. Arslan G, Kull B, and Fredholm BB (1999) Signaling via A2A adenosine receptor in four PC12 cell clones. Naunyn Schmiedebergs Arch Pharmacol 359:28-32. (Pubitemid 29142566)
6. 2B receptor. Mol Pharmacol 52:846-860.
7. 2B adenosine receptor from mouse, rabbit, and dog. J Pharmacol Exp Ther 329:2-13.
8. 1 receptor: synthesis and pharmacological evaluation of 4-substituted 2-amino-3- benzoylthiophenes. J Med Chem 52:4543-4547.
9. Avni I, Garzozi HJ, Barequet IS, Segev F, Varssano D, Sartani G, Chetrit N, Bakshi E, Zadok D, Tomkins O, et al. (2010) Treatment of dry eye syndrome with orally-administered CF101: data from a phase 2 clinical trial. Ophthalmology 117:1287-1293.
10. Ballarín M, Fredholm BB, Ambrosio S, and Mahy N (1991) Extracellular levels of adenosine and its metabolites in the striatum of awake rats: inhibition of uptake and metabolism. Acta Physiol Scand 142:97-103.
11. 1 adenosine receptor. Mini Rev Med Chem 7:559-569.
12. 1 allosteric enhancer. Bioorg Med Chem Lett 16:1402-1404.
13. Baraldi PG, Preti D, Tabrizi MA, Fruttarolo F, Romagnoli R, Carrion MD, Cara LC, Moorman AR, Varani K, and Borea PA (2007b) Synthesis and biological evaluation of novel 1-deoxy-1-[6-[((hetero)arylcarbonyl)hydrazine]-9H-purin-9- yl]-N-ethyl-β- D-ribofuranuronamide derivatives as useful templates for the development of A2B adenosine receptor agonists. J Med Chem 50:374-380. (Pubitemid 46147717)
14. 2B adenosine receptor antagonists. J Med Chem 47:1434-1447.
15. 1 adenosine receptor. Bioorg Med Chem Lett 10:1953-1957.
16. Barbhaiya H, McClain R, IJzerman A, and Rivkees SA (1996) Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues int he first four transmembrane domains on ligand binding. Mol Pharmacol 50:1635-1642. (Pubitemid 26425121)
17. Bastia E, Xu YH, Scibelli AC, Day YJ, Linden J, Chen JF, and Schwarzschild MA (2005) A crucial role for forebrain adenosine A(2A) receptors in amphetamine sensitization. Neuropsychopharmacology 30:891-900. (Pubitemid 40570905)
18. 2B receptors by radioligand binding studies. Purinergic Signal 2:559-571.
19. 2B receptor with an improved selectivity profile compared to the reference agonist N-ethylcarboxamidoadenosine. J Med Chem 47:3707-3709.
20. Beukers MW, Wanner MJ, Von Frijtag Drabbe Künzel JK, Klaasse EC, IJzerman AP, and Koomen GJ (2003) N6-Cyclopentyl-2-(3- phenylaminocarbonyltriazene-1- yl)adenosine (TCPA), a very selective agonist with high affinity for the human adenosine A1 receptor. J Med Chem 46:1492-1503. (Pubitemid 36512712)
21. Björklund O, Kahlström J, Salmi P, and Fredholm BB (2008) Perinatal caffeine, acting on maternal adenosine A1 receptors, causes long-lasting behavioral changes in mouse offspring. PloS One 3:e3977.
22. 2A adenosine receptor coupling with Gs. Biochem J 396:139-146.
23. Blackburn MR, Datta SK, and Kellems RE (1998) Adenosine deaminase-deficient mice generated using a two-stage genetic engineering strategy exhibit a combined immunodeficiency. J Biol Chem 273:5093-5100. (Pubitemid 28108669)
24. Boison D, Scheurer L, Zumsteg V, Rülicke T, Litynski P, Fowler B, Brandner S, and Mohler H (2002) Neonatal hepatic steatosis by disruption of the adenosine kinase gene. Proc Natl Acad Sci USA 99:6985-6990. (Pubitemid 34526244)
25. Borghi V, Przewlocka B, Labuz D, Maj M, Ilona O, and Pavone F (2002) Formalin-induced pain and mu-opioid receptor density in brain and spinal cord are modulated by A1 and A2a adenosine agonists in mice. Brain Res 956:339-348. (Pubitemid 35351401)
26. 2B receptor antagonists and a new radioligand with subnanomolar affinity and subtype specificity. J Med Chem 52:3994-4006.
27. Brackett LE and Daly JW (1994) Functional characterization of the A2b adenosine receptor in NIH 3T3 fibroblasts. Biochem Pharmacol 47:801-814.
28. Briddon SJ, Gandía J, Amaral OB, Ferré S, Lluís C, Franco R, Hill SJ, and Ciruela F (2008) Plasma membrane diffusion of G protein-coupled receptor oligomers. Biochim Biophys Acta 1783:2262-2268.
29. Brown R, Ollerstam A, Johansson B, Skøtt O, Gebre-Medhin S, Fredholm B, and Persson AE (2001) Abolished tubuloglomerular feedback and increased plasma renin in adenosine A1 receptor-deficient mice. Am J Physiol Regul Integr Comp Physiol 281:R1362-R1367.
30. Bruns RF (1980) Adenosine receptor activation in human fibroblasts: nucleoside agonists and antagonists. Can J Physiol Pharmacol 58:673-691.
31. 1 receptor binding by 2-amino-3-benzoylthiophenes. Mol Pharmacol 38:950-958.
32. Burnstock G (2006) Historical review: ATP as a neurotransmitter. Trends Pharmacol Sci 27:166-176.
33. 2A receptors form higher-order oligomers in living cells. J Neurochem 109:1497-1507.
34. Cagnina RE, Ramos SI, Marshall MA, Wang G, Frazier CR, and Linden J (2009) Adenosine A2B receptors are highly expressed on murine type II alveolar epithelial cells. Am J Physiol Lung Cell Mol Physiol 297:L467-L474.
35. 2A receptors: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Neurochem 88:726-734.
36. 2 receptorreceptor heteromerization: qualitative and quantitative assessment by fluorescence and bioluminescence energy transfer. J Biol Chem 278:46741-46749.
37. 2A adenosine receptor ligands. J Med Chem 53:3748-3755.
38. Carriba P, Navarro G, Ciruela F, Ferré S, Casadó V, Agnati L, Cortés A, Mallol J, Fuxe K, Canela EI, et al. (2008) Detection of heteromerization of more than two proteins by sequential BRET-FRET. Nat Methods 5:727-733.
39. Carriba P, Ortiz O, Patkar K, Justinova Z, Stroik J, Themann A, Müller C, Woods AS, Hope BT, Ciruela F, et al. (2007) Striatal adenosine A2A and cannabinoid CB1 receptors form functional heteromeric complexes that mediate the motor effects of cannabinoids. Neuropsychopharmacology 32:2249-2259. (Pubitemid 47587686)
40. Chabre M and le Maire M (2005) Monomeric G-protein-coupled receptor as a functional unit. Biochemistry 44:9395-9403. (Pubitemid 40962038)
41. Chabre M, Deterre P, and Antonny B. (2009) The apparent cooperativity of some GPCRs does not necessarily imply dimerization. Trends Pharmacol Sci 30:182-187.
42. Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Spanjersberg RF, Roerink SF, van den Hout G, Beukers MW, Brussee J, and IJzerman AP (2005) A series of ligands displaying a remarkable agonistic-antagonistic profile at the adenosine A1 receptor. J Med Chem 48:2045-2053. (Pubitemid 40396332)
43. Chang LC, von Frijtag Drabbe Künzel JK, Mulder-Krieger T, Westerhout J, Spangenberg T, Brussee J, and IJzerman AP (2007) 2,6,8-trisubstituted 1-deazapurines as adenosine receptor antagonists. J Med Chem 50:828-834. (Pubitemid 46332994)
44. 2A adenosine receptors. Neuroscience 97:195-204.
45. Chen JF, Huang Z, Ma J, Zhu J, Moratalla R, Standaert D, Moskowitz MA, Fink JS, and Schwarzschild MA (1999) A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischemia in mice. J Neurosci 19:9192-9200. (Pubitemid 30228071)
46. 2 receptor knockout mice. Proc Natl Acad Sci USA 98:1970-1975.
47. Chen JF, Sonsalla PK, Pedata F, Melani A, Domenici MR, Popoli P, Geiger J, Lopes LV, and de Mendonça A (2007) Adenosine A2A receptors and brain injury: broad spectrum of neuroprotection, multifaceted actions and "fine tuning" modulation. Prog Neurobiol 83:310-331. (Pubitemid 350119825)
48. Chen JF, Xu K, Petzer JP, Staal R, Xu YH, Beilstein M, Sonsalla PK, Castagnoli K, Castagnoli N Jr, and Schwarzschild MA (2001b) Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci 21:RC143.
49. Chen Y, Corriden R, Inoue Y, Yip L, Hashiguchi N, Zinkernagel A, Nizet V, Insel PA, and Junger WG (2006) ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. Science 314:1792-1795. (Pubitemid 44969094)
50. Childs E, Hohoff C, Deckert J, Xu K, Badner J, and de Wit H (2008) Association between ADORA2A and DRD2 polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology 33:2791-2800.
51. 1 adenosine receptor agonist allosteric enhancers having improved potency. J Med Chem 48:5131-5139.
52. 1 adenosine receptors in brain cortex. J Neurosci Res 42:818-828.
53. 2A receptor heteromers. J Neurosci 26:2080-2087.
54. Cohen FR, Lazareno S, and Birdsall NJ (1996) The affinity of adenosine for the high-and low-affinity states of the human adenosine A1 receptor. Eur J Pharmacol 309:111-114. (Pubitemid 26253025)
55. Conn PJ, Christopoulos A, and Lindsley CW (2009) Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat Rev Drug Discov 8:41-54.
56. 1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 14:631-640.
57. Daly JW, Hide I, Müller CE, and Shamim M (1991) Caffeine analogs: structure-activity relationships at adenosine receptors. Pharmacology 42:309-321.
58. Daly JW, Padgett WL, Secunda SI, Thompson RD, and Olsson RA (1993) Structureactivity relationships for 2-substituted adenosines at A1 and A2 adenosine receptors. Pharmacology 46:91-100. (Pubitemid 23041148)
59. Daly JW and Jacobson KA (1995) Adenosine and Andenine Nucleotides: from Molecular Biology to Integrative Physiology, Kluwer Academic Publishers, Boston.
60. 2a gene to the development of disease. Mol Psychiatry 3:81-85.
61. 1 receptor. Eur J Pharmacol 510:1-8.
62. Doggrell SA (2005) BG-9928 (Biogen Idec). Curr Opin Investig Drugs 6:962-968.
63. 2B adenosine receptor antagonists. Bioorg Med Chem Lett 20:1697-1700.
64. 2B adenosine receptors. Circulation 115:1581-1590.
65. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF, Park D, Woodson RI, Ostankovich M, Sharma P, et al. (2009) Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 461:282-286.
66. 2B adenosine receptor antagonist as a clinical candidate for chronic inflammatory airway diseases. J Med Chem 51:2267-2278.
67. 1 adenosine receptor agonists and their potential therapeutic applications. Expert Opin Investig Drugs 17:1901-1910.
68. El Yacoubi M, Ledent C, Ménard JF, Parmentier M, Costentin J, and Vaugeois JM (2000) The stimulant effects of caffeine on locomotor behaviour in mice are mediated through its blockade of adenosine A(2A) receptors. Br J Pharmacol 129:1465-1473. (Pubitemid 30175720)
69. Enjyoji K, Sévigny J, Lin Y, Frenette PS, Christie PD, Esch JS 2nd, Imai M, Edelberg JM, Rayburn H, Lech M, et al. (1999) Targeted disruption of cd39/ATP diphosphohydrolase results in disordered hemostasis and thromboregulation. Nat Med 5:1010-1017. (Pubitemid 29439571)
70. Fedele DE, Li T, Lan JQ, Fredholm BB, and Boison D (2006) Adenosine A(1) receptors are crucial in keeping an epileptic focus localized. Exp Neurol 200:184-190. (Pubitemid 44080760)
71. Ferré S, Baler R, Bouvier M, Caron MG, Devi LA, Durroux T, Fuxe K, George SR, Javitch JA, Lohse MJ, et al. (2009) Building a new conceptual framework for receptor heteromers. Nat Chem Biol 5:131-134.
72. 1 receptors in stably cotransfected fibroblast cells. J Biol Chem 273:4718-4724.
73. 2B receptors from rat, guinea pig and dog. Eur J Pharmacol 475:79-84.
74. Franchetti P, Cappellacci L, Marchetti S, Trincavelli L, Martini C, Mazzoni MR, Lucacchini A, and Grifantini M (1998) 2′-C-methyl analogues of selective adenosine receptor agonists: synthesis and binding studies. J Med Chem 41:1708-1715. (Pubitemid 28221965)
75. Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P, and Williams M (1994) Nomenclature and classification of purinoceptors. Pharmacol Rev 46:143-156. (Pubitemid 24984777)
76. Fredholm BB, Chen JF, Masino SA, and Vaugeois JM (2005) Actions of adenosine at its receptors in the CNS: insights from knockouts and drugs. Annu Rev Pharmacol Toxicol 45:385-412. (Pubitemid 40261811)
77. Fredholm BB, IJzerman AP, Jacobson KA, Klotz KN, and Linden J (2001a) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53:527-552.
78. Fredholm BB, Irenius E, Kull B, and Schulte G (2001b) Comparison of the potency of adenosine as an agonist at human adenosine receptors expressed in Chinese hamster ovary cells. Biochem Pharmacol 61:443-448. (Pubitemid 32168226)
79. Gandia J, Galino J, Amaral OB, Soriano A, Lluís C, Franco R, and Ciruela F (2008) Detection of higher-order G protein-coupled receptor oligomers by a combined BRET-BiFC technique. FEBS Lett 582:2979-2984.
80. 2A adenosine receptors by amiloride analogues and sodium ions. Biochem Pharmacol 60:669-676.
81. 3 adenosine receptors by a series of 3-(2- pyridinyl)isoquinoline derivatives. Mol Pharmacol 60:1057-1063.
82. 3 adenosine receptors by a series of imidazoquinoline derivatives. Mol Pharmacol 62:81-89.
83. 3 adenosine receptor. Mol Pharmacol 63:1021-1031.
84. 3 adenosine receptors. Biochem Pharmacol 65:525-534.
85. Gao ZG, Kim SK, IJzerman AP, and Jacobson KA (2005) Allosteric modulation of the adenosine family of receptor. Mini Rev Med Chem 5:545-553. (Pubitemid 40754168)
86. Gao ZG, Ye K, Göblyös A, IJzerman AP, and Jacobson KA. (2008) Flexible modulation of agonist efficacy at the human A3 adenosine receptor by the imidazoquinoline allosteric enhancer LUF6000. BMC Pharmacol 8:20.
87. 3 adenosine receptor. J Pharmacol Exp Ther 319:1200-1210.
88. 2A receptor. 4. Design, synthesis, and preclinical evaluation of 7-aryltriazolo[4,5-d]pyrimidines. J Med Chem 52:33-47.
89. 1 receptors form functionally interacting heteromeric complexes. Proc Natl Acad Sci USA 97:8606-8611.
90. 2A adenosine receptors. Eur J Med Chem 43:1639-1647.
91. Göblyös A, Santiago SN, Pietra D, Mulder-Krieger T, von Frijtag Drabbe Künzel J, Brussee J, and IJzerman AP (2005) Synthesis and biological evaluation of 2-aminothiazoles and their amide derivatives on human adenosine receptors. Lack of effect of 2-aminothiazoles as allosteric enhancers. Bioorg Med Chem 13:2079-2087.
92. Göblyös A, Gao ZG, Brussee J, Connestari R, Santiago SN, Ye K, IJzerman AP, and Jacobson KA (2006) Structure activity relationships of 1H-imidazo[4,5-c]quinolin-4-amine derivatives new as allosteric enhancers of the A3 adenosine receptor. J Med Chem 49:3354-3361. (Pubitemid 43830533)
93. Goldman N, Chen M, Fujita T, Xu Q, Peng W, Liu W, Jensen TK, Pei Y, Wang F, Han X, et al. (2010) Adenosine A1 receptors mediate local anti-nociceptive effects of acupuncture. Nat Neurosci 13:883-888.
94. 2-adenosine receptor antagonists. J Med Chem 37:1526-1534.
95. 3 adenosine receptor confers resistance to myocardial ischemic injury and does not prevent early preconditioning. J Mol Cell Cardiol 33:825-830.
96. Hamilton SP, Slager SL, De Leon AB, Heiman GA, Klein DF, Hodge SE, Weissman MM, Fyer AJ, and Knowles JA (2004) Evidence for genetic linkage between a polymorphism in the adenosine 2A receptor and panic disorder. Neuropsychopharmacology 29:558-565. (Pubitemid 38365933)
97. Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, Sussman NM, and Istradefylline 6002-US-013 Study Group (2008) Study of istradefylline in patients with Parkinson's disease on levodopa with motor fluctuations. Mov Disord 23:2177-2185.
98. 2B-selective adenosine receptor antagonists. J Med Chem 45:1500-1510.
99. 3 receptor. J Med Chem 52:926-931.
100. 1 receptors of LUF5831, a novel nonadenosine-like agonist. Br J Pharmacol 147:533-541.
101. Hider SL, Thomson W, Mack LF, Armstrong DJ, Shadforth M, and Bruce IN (2008) Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. Rheumatology (Oxford) 47:1156-1159. (Pubitemid 352038219)
102. 2 receptors. J Biol Chem 277:18091-18097.
103. 2A receptor gene: evidence for association of risk variants with panic disorder and anxious personality. J Psychiatr Res 44:930-937.
104. 1- adenosine receptor antagonist for in vivo imaging. J Med Chem 45:5150-5156.
105. Hua X, Chason KD, Fredholm BB, Deshpande DA, Penn RB, and Tilley SL (2008) Adenosine induces airway hyperresponsiveness through activation of A3 receptors on mast cells. J Allergy Clin Immunol 122:107-113.
106. Hua X, Erikson CJ, Chason KD, Rosebrock CN, Deshpande DA, Penn RB, and Tilley SL (2007a) Involvement of A1 adenosine receptors and neural pathways in adenosine-induced bronchoconstriction in mice. Am J Physiol Lung Cell Mol Physiol 293:L25-L32. (Pubitemid 47080711)
107. Hua X, Kovarova M, Chason KD, Nguyen M, Koller BH, and Tilley SL (2007b) Enhanced mast cell activation in mice deficient in the A2b adenosine receptor. J Exp Med 204:117-128. (Pubitemid 46148762)
108. 2A receptors in bone marrow-derived cells but not in forebrain neurons are important contributors to 3-nitropropionic acid-induced striatal damage as revealed by cell-type-selective inactivation. J Neurosci 26:11371-11378.
109. 1, receptors mediate the arousal effect of caffeine. Nat Neurosci 8:858-859.
110. Hussey MJ, Clarke GD, Ledent C, Hourani SM, and Kitchen I (2007) Reduced response to the formalin test and lowered spinal NMDA glutamate receptor binding in adenosine A2A receptor knockout mice. Pain 129:287-294. (Pubitemid 46754569)
111. 2A adenosine receptor crystallographic structure. J Med Chem 52:3284-3292.
112. 2A adenosine receptor bound to an antagonist. Science 322:1211-1217.
113. Jacobson KA (2009) Introduction to adenosine receptors as therapeutic targets. Handbook of Experimental Pharmacology 193:1-24.
114. 2-selective adenosine antagonists. J Med Chem 36:1333-1342.
115. 1-adenosine receptors. Bioconjugate Chem 6:255-263.
116. 2B adenosine receptors. Drug Dev Res 47:45-53.
117. Jacobson KA and Gao ZG (2006) Adenosine receptors as therapeutic targets. Nat Rev Drug Discov 5:247-264. (Pubitemid 43336037)
118. 2A antagonists and Parkinson's disease. Parkinsonism Relat Disord 15:406-413.
119. Jin X, Shepherd RK, Duling BR, and Linden J (1997) Inosine binds to A3 adenosine receptors and stimulates mast cell degranulation. J Clin Invest 100:2849-2857. (Pubitemid 28007555)
120. 1 receptor. Proc Natl Acad Sci USA 98:9407-9412.
121. 1 receptors regulate lipolysis and lipogenesis in mouse adipose tissueinteractions with insulin. Eur J Pharmacol 597:92-101.
122. Johansson SM, Salehi A, Sandström ME, Westerblad H, Lundquist I, Carlsson PO, Fredholm BB, and Katz A (2007a) A1 receptor deficiency causes increased insulin and glucagon secretion in mice. Biochem Pharmacol 74:1628-1635. (Pubitemid 47614964)
123. Johansson SM, Yang JN, Lindgren E, and Fredholm BB (2007b) Eliminating the antilipolytic adenosine A1 receptor does not lead to compensatory changes of PGE2 or nicotinic acid effects on lipolysis. Acta Physiologica 190:87-96. (Pubitemid 46570175)
124. 1 receptor antagonist SLV320 reduces myocardial fibrosis in rats with 5/6 nephrectomy without affecting blood pressure. Br J Pharmacol 151:1025-1032.
125. 2 receptors in living cells. Biochem Biophys Res Commun 306:544-549.
126. Kara FM, Chitu V, Sloane J, Axelrod M, Fredholm BB, Stanley ER, and Cronstein BN (2010a) Adenosine A1 receptors (A1R) regulate bone resorption adenosine A1R play a critical role in osteoclast formation and function. FASEB J 24:2325-2333.
127. 1 receptors regulate bone homeostasis: adenosine A1R blockade or deletion increase bone density and prevents ovariectomy-induced bone loss. Arthritis Rheum 62:534-541.
128. 2A receptor selective antagonist KW6002: research toward a novel nondopaminergic therapy for Parkinson's disease. Neurology 61 (Suppl 6):S97-S100.
129. 2A receptor antagonists. J Med Chem 53:1799-1809.
130. Kecskés M, Kumar TS, Yoo L, Gao ZG, and Jacobson KA (2010) Novel
131. 1 receptor antagonists. Bioorg Med Chem 14:3654-3661.
132. Kiesman WF, Zhao J, Conlon PR, Dowling JE, Petter RC, Lutterodt F, Jin X, Smits G, Fure M, Jayaraj A, et al. (2006b) Potent and orally bioavailable 8-bicyclo[2.2.2]octylxanthines as adenosine A1 receptor antagonists. J Med Chem 49:7119-7131. (Pubitemid 44885997)
133. 2a adenosine receptors are required for ligand recognition. Mol Pharmacol, 49:683-691.
134. 2B adenosine receptors of xanthine derivatives substituted at the 1-, 3-, 7-, and 8-positions. J Med Chem 45:2131-2138.
135. Kim SH, Kim YK, Park HW, Kim SH, Kim SH, Ye YM, Min KU, and Park HS (2009a) Adenosine deaminase and adenosine receptor polymorphisms in aspirin-intolerant asthma. Respir Med 103:356-363.
136. 3 adenosine receptor. J Med Chem 52:2098-2108.
137. Kim YC, Ji X, Melman N, Linden J, and Jacobson KA (2000) Anilide derivatives of an 8-phenylxanthine carboxylic congener are highly potent and selective antagonists at human A2B adenosine receptors. J Med Chem 43:1165-1172. (Pubitemid 30173742)
138. King AE, Ackley MA, Cass CE, Young JD, and Baldwin SA (2006) Nucleoside transporters: from scavengers to novel therapeutic targets. Trends Pharmacol Sci 27:416-425. (Pubitemid 44051567)
139. 1 adenosine receptors in brain from different species by radioligand binding and photoaffinity labelling. Naunyn Schmiedebergs Arch Pharmacol 343:196-201.
140. Klotz KN, Hessling J, Hegler J, Owman C, Kull B, Fredholm BB, and Lohse MJ (1998) Comparative pharmacology of human adenosine receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn Schmiedebergs Arch Pharmacol 357:1-9. (Pubitemid 28085115)
141. Klotz KN, Falgner N, Kachler S, Lambertucci C, Vittori S, Volpini R, and Cristalli G (2007) [3H]HEMADO - a novel tritiated agonist selective for the human adenosine A3 receptor. Eur J Pharmacol 556:14-18. (Pubitemid 46073996)
142. 1 receptor knockout mice develop lethal status epilepticus after experimental traumatic brain injury. J Cereb Blood Flow Metab 26:565-575.
143. Koszalka P, Ozüyaman B, Huo Y, Zernecke A, Flögel U, Braun N, Buchheiser A, Decking UK, Smith ML, Sévigny J, et al. (2004) Targeted disruption of cd73/ecto- 5′-nucleotidase alters thromboregulation and augments vascular inflammatory response. Circ Res 95:814-821. (Pubitemid 39390584)
144. Kourounakis AP, van de Klein PA, and IJzerman AP (2000) Elucidation of structure-activity relationships of 2-amino-3-benzoylthiophenes: study of their allosteric enhancing vs. antagonistic activity on adenosine A1 receptors. Drug Dev Res 49:227-237. (Pubitemid 30418419)
145. 1 receptor. Biochem Pharmacol 61:137-144.
146. 2b-dependent signalling during early reperfusion. J Mol Cell Cardiol 43:262-271.
147. 3 adenosine receptor. Biochem Pharmacol 79:48-56.
148. 1 adenosine receptor expression on protection with ischemic preconditioning. Am J Physiol Heart Circ Physiol 290:H1469-H1473.
149. Lappas CM, Rieger JM, and Linden J (2005) A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells. J Immunol 174:1073-1080. (Pubitemid 40094304)
150. Lazarowski ER, Boucher RC, and Harden TK (2000) Constitutive release of ATP and evidence for major contribution of ecto-nucleotide pyrophosphatase and nucleoside diphosphokinase to extracellular nucleotide concentrations. J Biol Chem 275:31061-31068.
151. Lazarowski ER, Boucher RC, and Harden TK (2003) Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol 64:785-795. (Pubitemid 37153046)
152. 2A receptor. Nature 388:674-678.
153. 2A receptor antagonist istradefylline (KW- 6002) reduces "off" time in Parkinson's disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008 Mar;63:295-302.
154. 3 Adenosine Receptors from Cell Biology to Pharmacology (Borea P ed) pp 257-280, Springer, Berlin.
155. Li X, Conklin D, Pan HL, and Eisenach JC (2003) Allosteric adenosine receptor modulation reduces hypersensitivity following peripheral inflammation by a central mechanism. J Pharmacol Exp Ther 305:950-955. (Pubitemid 36617972)
156. Li T, Quan Lan J, Fredholm BB, Simon RP, and Boison D (2007) Adenosine dysfunction in astrogliosis: cause for seizure generation? Neuron Glia Biol 3:353-366.
157. Libert F, Schiffmann SN, Lefort A, Parmentier M, Gérard C, Dumont JE, Vanderhaeghen JJ, and Vassart G (1991) The orphan receptor cDNA RDC7 encodes an A1 adenosine receptor. EMBO J 10:1677-1682. (Pubitemid 21905634)
158. Lukashev DE, Smith PT, Caldwell CC, Ohta A, Apasov SG, and Sitkovsky MV (2003) Analysis of A2a receptor-deficient mice reveals no significant compensatory increases in the expression of A2b, A1, and A3 adenosine receptors in lymphoid organs. Biochem Pharmacol 65:2081-2090. (Pubitemid 36629591)
159. MacDonald PE, Braun M, Galvanovskis J, and Rorsman P (2006) Release of small transmitters through kiss-and-run fusion pores in rat pancreatic beta cells. Cell Metab 4:283-290. (Pubitemid 44430913)
160. Maenhaut C, Van Sande J, Libert F, Abramowicz M, Parmentier M, Vanderhaegen JJ, Dumont JE, Vassart G, and Schiffmann S (1990) RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem Biophys Res Commun 173:1169-1178.
161. 2a receptor. Proc Natl Acad Sci USA 105:10744-10749.
162. Masino SA, Diao L, Illes P, Zahniser NR, Larson GA, Johansson B, Fredholm BB, and Dunwiddie TV (2002) Modulation of hippocampal glutamatergic transmission by ATP is dependent on adenosine A(1) receptors. J Pharmacol Exp Ther 303:356-363.
163. May LT, Sexton PM, and Christopoulos A (2005) Effects of urea pretreatment on the binding properties of adenosine A1 receptors. Br J Pharmacol 146:1119-1129. (Pubitemid 41785323)
164. 3 receptor-selective agonists. Bioorg Med Chem Lett 18:2813-2819.
165. Michino M, Abola E, GPCR Dock 2008 participants, Brooks CL 3rd, Dixon JS, Moult J, and Stevens RC (2009) Community-wide assessment of GPCR structure modelling and ligand docking: GPCR Dock 2008. Nat Rev Drug Discov 8:455-463.
166. 2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization. J Med Chem 48:6887-6896.
167. Mobarec JC, Sanchez R, and Filizola M (2009) Modern homology modeling of G-protein coupled receptors: which structural template to use? J Med Chem 52:5207-5216.
168. Montesinos MC, Desai A, Chen JF, Yee H, Schwarzschild MA, Fink JS, and Cronstein BN (2002) Adenosine promotes wound healing and mediates angiogenesis in response to tissue injury via occupancy of A(2A) receptors. Am J Pathol 160:2009-2018. (Pubitemid 34663394)
169. Morrison RR, Talukder MA, Ledent C, and Mustafa SJ (2002) Cardiac effects of adenosine in A(2A) receptor knockout hearts: uncovering A(2B) receptors. Am J Physiol Heart Circ Physiol 282:H437-H444. (Pubitemid 34654966)
170. 2A Adenosine receptor antagonists - future drugs for Parkinson's disease? Drugs Future 25:1043-1052.
171. Müller CE (2000b) Adenosine receptor ligands-recent developments part I. Agonists. Curr Med Chem 7:1269-1288.
172. 3 adenosine receptors. Bioorg Med Chem Lett 12:501-503.
173. 2A receptors: a new strategy for basal ganglia disorders. Recent Pat CNS Drug Discov 2:1-21.
174. Müller CE and Jacobson KA (2011) Recent developments in adenosine receptor ligands and their potential as novel drugs. Biochim Biophys Acta doi: 10.1016/j.bbamem.2010.12.017.
175. 2A adenosine receptors. Eur J Pharm Sci 10:259-265.
176. Müller CE, Shi D, Manning M Jr, and Daly JW (1993b) Synthesis of paraxanthine analogs (1,7-disubstituted xanthines) and other xanthines unsubstituted at the 3-position: structure-activity relationships at adenosine receptors. J Med Chem 36:3341-3349. (Pubitemid 23335698)
177. Müller CE and Stein B (1996) Adenosine receptor antagonists: structures and potential therapeutic applications. Curr Pharm Des 2:501-530. (Pubitemid 126471649)
178. 3-adenosine receptor antagonists. J Med Chem 45:3440-3450.
179. 2A adenosine receptor induction. Biochem J 391: 575-580.
180. Nakata H, Yoshioka K, Kamiya T, Tsuga H, and Oyanagi K (2005) Functions of heteromeric association between adenosine and P2Y receptors. J Mol Neurosci 26:233-238. (Pubitemid 41389415)
181. 1 receptor. J Med Chem 53:3028-3037.
182. 2 receptors. J Biol Chem 284:28058-28068.
183. 2A G-protein-coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 8:1088-1097.
184. Newby AC (1984) Adenosine and the concept of "retaliatory metabolites". Trends Biochem 9:42-44.
185. 1 receptor allosteric enhancers. Bioorg Med Chem 14:2358-2365.
186. 3 adenosine receptor is over-expressed in rheumatoid arthritis, psoriasis and Crohn's disease. Cell Immunol 258:115-122.
187. Ohta A, Lukashev D, Jackson EK, Fredholm BB, and Sitkovsky M (2007) 1,3,7- Trimethylxanthine (caffeine) may exacerbate acute inflammatory liver injury by weakening the physiological immunosuppressive mechanism. J Immunol 179:7431-7438.
188. Ohta A and Sitkovsky M (2001) Role of G-protein-coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414:916-920. (Pubitemid 34024743)
189. 1 receptors and promotes non-rapid eye movement sleep. Proc Natl Acad Sci USA 105:19992-19997.
190. Okada SF, Nicholas RA, Kreda SM, Lazarowski ER, and Boucher RC (2006) Physiological regulation of ATP release at the apical surface of human airway epithelia. J Biol Chem 281:22992-23002.
191. 3 adenosine receptors. Bioorg Med Chem 11:347-356.
192. Parkinson FE and Fredholm BB (1992) Magnesium-dependent enhancement of endogenous agonist binding to A1 adenosine receptors: a complicating factor in quantitative autoradiography. J Neurochem 58:941-950.
193. 1-adenosine antagonist 1,3-dipropyl-8-[2-(5,6-epoxynorbornyl)]xanthine. J Med Chem 40:1773-1778.
194. Picher M, Burch LH, Hirsh AJ, Spychala J, and Boucher RC (2003) Ecto 5′-nucleotidase and nonspecific alkaline phosphatase. Two AMP-hydrolyzing ectoenzymes with distinct roles in human airways. J Biol Chem 278:13468-13479. (Pubitemid 36800121)
195. Pin JP, Neubig R, Bouvier M, Devi L, Filizola M, Javitch JA, Lohse MJ, Milligan G, Palczewski K, Parmentier M, et al. (2007) International Union of Basic and Clinical Pharmacology. LXVII. Recommendations for the recognition and nomenclature of G protein-coupled receptor heteromultimers. Pharmacol Rev 59:5-13.
196. 2A receptor antagonists for Parkinson's disease. Expert opinion on investigational drugs 18:1619-1631.
197. Popescu FD and Popescu F (2007) A review of antisense therapeutic interventions for molecular biological targets in asthma. Biologics 1:271-283.
198. 2A receptor by (E,E)-8-(4-phenylbutadien-1-yl)caffeine analogues. Bioorg Med Chem 16:8676-8684.
199. Rétey JV, Adam M, Honegger E, Khatami R, Luhmann UF, Jung HH, Berger W, and Landolt HP (2005) A functional genetic variation of adenosine deaminase affects the duration and intensity of deep sleep in humans. Proc Natl Acad Sci USA 102:15676-15681. (Pubitemid 41528115)
200. Rétey JV, Adam M, Khatami R, Luhmann UF, Jung HH, Berger W, and Landolt HP (2007) A genetic variation in the adenosine A2A receptor gene (ADORA2A) contributes to individual sensitivity to caffeine effects on sleep. Clin Pharmacol Ther 81:692-698. (Pubitemid 46625104)
201. Reutershan J, Cagnina RE, Chang D, Linden J, and Ley K (2007) Therapeutic anti-inflammatory effects of myeloid cell adenosine receptor A2a stimulation in lipopolysaccharide-induced lung injury. J Immunol 179:1254-1263.
202. Riksen NP, Zhou Z, Oyen WJ, Jaspers R, Ramakers BP, Brouwer RM, Boerman OC, Steinmetz N, Smits P, and Rongen GA (2006) Caffeine prevents protection in two human models of ischemic preconditioning. J Am Coll Cardiol 48:700-707. (Pubitemid 44175737)
203. 2B-adenosine receptor. Mol Endocrinol 6:1598-1604.
204. Robson SC, Wu Y, Sun X, Knosalla C, Dwyer K, and Enjyoji K (2005) Ectonucleotidases of CD39 family modulate vascular inflammation and thrombosis in transplantation. Semin Thromb Hemost 31:217-233. (Pubitemid 40605196)
205. Romano C, Yang WL, and O'Malley KL (1996) Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J Biol Chem 271:28612-28616. (Pubitemid 26374686)
206. 1 adenosine receptor. J Med Chem 51:5875-5879.
207. 2A receptor activation reduces infarct size in the isolated, perfused mouse heart by inhibiting resident cardiac mast cell degranulation. Am J Physiol Heart Circ Physiol 295:H1825-H1833.
208. Rosenbaum DM, Rasmussen SG, and Kobilka BK (2009) The structure and function of G-protein-coupled receptors. Nature 459:356-363.
209. Rovira X, Pin JP, and Giraldo J (2010) The asymmetric/symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. Trends Pharmacol Sci 31:15-21.
210. 2B adenosine receptor gene ablation on adenosine-dependent regulation of proinflammatory cytokines. J Pharmacol Exp Ther 324:694-700.
211. 2A receptor gene polymorphism. Eur Heart J 30:1510-1515.
212. Sajjadi FG, Takabayashi K, Foster AC, Domingo RC, and Firestein GS (1996) Inhibition of TNF-alpha expression by adenosine: role of A3 adenosine receptors. J Immunol 156:3435-3442. (Pubitemid 26124449)
213. Saki M, Tsumuki H, Nonaka H, Shimada J, and Ichimura M (2002) KF26777 (2-(4-bromophenyl)-7,8-dihydro-4-propyl-1H-imidazo[2,1-i]purin-5(4H)-one dihydrochloride), a new potent and selective adenosine A3 receptor antagonist. Eur J Pharmacol 444:133-141. (Pubitemid 34626830)
214. 3 adenosine receptor. Proc Natl Acad Sci USA 90:10365-10369.
215. Salvatore CA, Tilley SL, Latour AM, Fletcher DS, Koller BH, and Jacobson MA (2000) Disruption of the A(3) adenosine receptor gene in mice and its effect on stimulated inflammatory cells. J Biol Chem 275:4429-4434. (Pubitemid 30094686)
216. 2Aselective adenosine receptor antagonists. J Med Chem 43:440-448.
217. 1 adenosine receptors in pig brain cortical membranes. J Neurochem 66:1675-1682.
218. 1 receptor in adult mice using an adenoassociated viral vector. J Neurosci 23:5762-5770.
219. 3 receptors expressed in Chinese hamster ovary cells all mediate the phosphorylation of extracellular-regulated kinase 1/2. Mol Pharmacol 58:477-482.
220. Schulte G, Sommerschild H, Yang J, Tokuno S, Goiny M, Lövdahl C, Johansson B, Fredholm BB, and Valen G (2004) Adenosine A receptors are necessary for protection of the murine heart by remote, delayed adaptation to ischaemia. Acta Physiol Scand 182:133-143. (Pubitemid 39371860)
221. Schwartz TW and Holst B (2006) Ago-allosteric modulation and other types of allostery in dimeric 7TM receptors. J Recept Signal Transduct Res 26:107-128.
222. Shen HY, Coelho JE, Ohtsuka N, Canas PM, Day YJ, Huang QY, Rebola N, Yu L, Boison D, Cunha RA, et al. (2008) A critical role of the adenosine A2A receptor in extrastriatal neurons in modulating psychomotor activity as revealed by opposite phenotypes of striatum and forebrain A2A receptor knock-outs. J Neurosci 28: 2970-2975. (Pubitemid 351442271)
223. 2A antagonists with potent anti-cataleptic activity. Bioorg Med Chem Lett 7:2349-2352.
224. 1 receptors in the discriminative-stimulus effects of caffeine in rats. Psychopharmacology 179:576-586.
225. Spray DC, Ye ZC, and Ransom BR (2006) Functional connexin "hemichannels": a critical appraisal. Glia 54:758-773.
226. Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, and Sussman NM (2008) A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease [published erratum appears in Neurology 71:953, 2008]. Neurology 70:2233-2240.
227. Stenberg D, Litonius E, Halldner L, Johansson B, Fredholm BB, and Porkka-Heiskanen T (2003) Sleep and its homeostatic regulation in mice lacking the adenosine A1 receptor. J Sleep Res 12:283-290. (Pubitemid 38010434)
228. Sun D, Samuelson LC, Yang T, Huang Y, Paliege A, Saunders T, Briggs J, and Schnermann J (2001) Mediation of tubuloglomerular feedback by adenosine: evidence from mice lacking adenosine 1 receptors. Proc Natl Acad Sci USA 98:9983-9988. (Pubitemid 32769414)
229. 2 receptor. Biochem Biophys Res Commun 351:559-565.
230. 1 adenosine receptor is essential for ligand binding but not receptor homodimerization. J Neurochem 110:1352-1362.
231. 2A receptors. Prog Neurobiol 59:355-396.
232. Tang Z, Diamond MA, Chen JM, Holly TA, Bonow RO, Dasgupta A, Hyslop T, Purzycki A, Wagner J, McNamara DM, et al. (2007) Polymorphisms in adenosine receptor genes are associated with infarct size in patients with ischemic cardiomyopathy. Clin Pharmacol Ther 82:435-440. (Pubitemid 47414354)
233. Tawfik HE, Schnermann J, Oldenburg PJ, and Mustafa SJ (2005) Role of A1 adenosine receptors in regulation of vascular tone. Am J Physiol Heart Circ Physiol 288:H1411-H1416. (Pubitemid 40270052)
234. 2A adenosine receptor knockout mouse coronary artery. J Mol Cell Cardiol 44:905-914.
235. Thompson LF, Eltzschig HK, Ibla JC, Van De Wiele CJ, Resta R, Morote-Garcia JC, and Colgan SP (2004) Crucial role for ecto-5′- nucleotidase (CD73) in vascular leakage during hypoxia. J Exp Med 200:1395-1405. (Pubitemid 39657287)
236. Tilley SL, Wagoner VA, Salvatore CA, Jacobson MA, and Koller BH (2000) Adenosine and inosine increase cutaneous vasopermeability by activating A3 receptors on mast cells. J Clin Invest 105:361-367. (Pubitemid 30094456)
237. 1 receptors in stably cotransfected fibroblast cells and neurons. Neuroscience 113:709-719.
238. 3 heteromeric complexes. Mol Pharmacol 67:400-407.
239. 3 receptors reduce ischemic myocardial injury. Am J Physiol Heart Circ Physiol 285:H2780-H2787.
240. Ukena D, Jacobson KA, Padgett WL, Ayala C, Shamim MT, Kirk KL, Olsson RO, and Daly JW (1986b) Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett 209:122-128. (Pubitemid 17224579)
241. 1 receptor allosteric modulators. Mol Pharmacol 78:444-455.
242. 1 receptor: synthesis and biological evaluation of novel 2-amino- 3-benzoylthiophenes as allosteric enhancers of agonist binding. J Med Chem 42:3629-3635.
243. van Galen PJ, Nissen P, van Wijngaarden I, IJzerman AP, and Soudijn W (1991) 1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. J Med Chem 34:1202-1206.
244. 3 adenosine receptor. Mol Pharmacol 45:1101-1111.
245. 3 receptor ligands. 1. 3-(2-Pyridinyl)isoquinoline derivatives. J Med Chem 41:3987-3993.
246. van Muijlwijk-Koezen JE, Timmerman H, van der Goot H, Menge WM, Frijtag Von Drabbe Künzel J, de Groote M, and IJzerman AP (2000) Isoquinoline and quinazoline urea analogues as antagonists for the human adenosine A3 receptors. J Med Chem 43:2227-2238. (Pubitemid 30354547)
247. 3 receptors are overexpressed in pleura from mesothelioma patients and reduce cell growth via Akt/NF-kB pathway. Am J Resp Crit Care Med doi:10.1164/rccm.201006-0980OC.
248. Varani K, Vincenzi F, Tosi A, Targa M, Masieri FF, Ongaro A, De Mattei M, Massari L, and Borea PA (2010) Expression and functional role of adenosine receptors in regulating inflammatory responses in human synoviocytes. Br J Pharmacol 160:101-115.
249. 2B adenosine receptor antagonist. J Med Chem 50:2732-2736.
250. 2A receptors in living neuronal cells. Mol Pharmacol 74:544-551.
251. 2A receptors assemble into higher-order oligomers at the plasma membrane. FEBS Lett 582:3985-3990.
252. Volpini R, Costanzi S, Lambertucci C, Taffi S, Vittori S, Klotz KN, and Cristalli G (2002) N6-alkyl-2-alkynyl derivatives of adenosine as potent and selective agonists at the human adenosine A3 receptor and a starting point for searching A2B ligands. J Med Chem 45:3271-3279. (Pubitemid 34774277)
253. 3 receptor. J Med Chem 52:7897-7900.
254. 3 adenosine receptor agonist CP-532,903 [N6-(2,5-dichlorobenzyl)-3′-aminoadenosine-5′-N- methylcarboxamide] protects against myocardial ischemia/reperfusion injury via the sarcolemmal ATP-sensitive potassium channel. J Pharmacol Exp Ther 324:234-243.
255. 1 receptors and vascular reactivity. Acta Physiol (Oxf) 199:211-220.
256. Wendler CC, Amatya S, McClaskey C, Ghatpande S, Fredholm BB, and Rivkees SA (2007) A1 adenosine receptors play an essential role in protecting the embryo against hypoxia. Proc Natl Acad Sci USA 104:9697-9702. (Pubitemid 47175329)
257. 1 receptor antagonists: xanthines modified at position 3 and related pyrimido[1,2,3- cd]purinediones. ChemMedChem 1:891-902.
258. White JF, Grodnitzky J, Louis JM, Trinh LB, Shiloach J, Gutierrez J, Northup JK, and Grisshammer R.K. & Grisshammer, R. (2007) Dimerization of the class A G protein-coupled neurotensin receptor NTS1 alters G protein interaction. Proc Natl Acad Sci USA 104:12199-12204. (Pubitemid 47189413)
259. Whorton MR, Bokoch MP, Rasmussen SG, Huang B, Zare RN, Kobilka B, and Sunahara RK (2007) A monomeric G protein-coupled receptor isolated in a high-density lipoprotein particle efficiently activates its G protein. Proc Natl Acad Sci USA 104:7682-7687. (Pubitemid 47185966)
260. Whorton MR, Jastrzebska B, Park PS, Fotiadis D, Engel A, Palczewski, K. & Sunahara, R.K., (2008)Efficient coupling of transducin to monomeric rhodopsin in a phospholipid bilayer. J Biol Chem 283:4387-4394.
261. Wilson CN and Mustafa SJ (2009) Adenosine receptors in health and disease. Handb Exp Pharmacol 193:1-652.
262. 3 receptors. Neuroscience 114:523-527.
263. 1 receptor. Pain 113:395-404.
264. Yaar R, Jones MR, Chen JF, and Ravid K (2005) Animal models for the study of adenosine receptor function. J Cell Physiol 202:9-20. (Pubitemid 39603358)
265. Yan L, Burbiel JC, Maass A, and Müller CE (2003) Adenosine receptor agonists: from basic medicinal chemistry to clinical development. Expert Opin Emerg Drugs 8:537-576. (Pubitemid 37522665)
266. Yang D, Koupenova M, McCrann DJ, Kopeikina KJ, Kagan HM, Schreiber BM, and Ravid K (2008) The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci USA 105:792-796. (Pubitemid 351171787)
267. 2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest 116:1913-1923.
268. 2A adenosine receptors in regulating heart rate, body temperature, and locomotion as revealed using knockout mice and caffeine. Am J Physiol Heart Circ Physiol 296:H1141-H1149.
269. 2A adenosine receptor genes show similarities to mice given long-term caffeine. J Appl Physiol 106:631-639.
270. Yang JN, Tiselius C, Daré E, Johansson B, Valen G, and Fredholm BB (2007) Sex differences in mouse heart rate and body temperature and in their regulation by adenosine A1 receptors. Acta Physiologica 190:63-75. (Pubitemid 46570173)
271. 2A receptor activation is due to its action on CD4+ T lymphocytes. Circulation 114:2056-2064.
272. 1 receptors with P2Y1 receptors in rat brains. FEBS Lett 531:299-303.
273. Yoshioka K, Saitoh O, and Nakata H (2001) Heteromeric association creates a P2Y-like adenosine receptor. Proc Natl Acad Sci USA 98:7617-7622. (Pubitemid 32567997)
274. Zhang Q, Li Y, and Tsien RW (2009) The dynamic control of kiss-and-run and vesicular reuse probed with single nanoparticles. Science 323:1448-1453.
275. Zhang Z, Chen G, Zhou W, Song A, Xu T, Luo Q, Wang W, Gu XS, and Duan S (2007) Regulated ATP release from astrocytes through lysosome exocytosis. Nat Cell Biol 9:945-953. (Pubitemid 47190449)
276. 3 adenosine receptor. Proc Natl Acad Sci USA 89:7432-7436.